| Record ID | marc_columbia/Columbia-extract-20221130-008.mrc:528655357:1478 |
| Source | marc_columbia |
| Download Link | /show-records/marc_columbia/Columbia-extract-20221130-008.mrc:528655357:1478?format=raw |
LEADER: 01478cam a2200325 a 4500
001 3969671
005 20221027011720.0
008 921120t19911991nz a b 100 0 eng d
035 $a(OCoLC)30504592
035 $a(OCoLC)ocm30504592
035 $9AGM5165HS
035 $a(NNC)3969671
035 $a3969671
040 $aNNC-M$cNNC-M
245 00 $aFosinopril :$bthe profile of a new ACE inhibitor : a seminar-in-print /$cguest editor, Norman M. Kaplan ; technical editors, Kerry Dechant [and others].
260 $aAuckland, New Zealand :$bADIS International Ltd.,$c[1991], ©1991.
300 $a53 pages :$billustrations ;$c25 cm.
336 $atext$btxt$2rdacontent
337 $aunmediated$bn$2rdamedia
490 1 $aDrug investigation supplement ;$vv. 3, suppl. 4
504 $aIncludes bibliographical references.
500 $a"Sponsored by Bristol-Myers Squibb Company, Princeton, New Jersey, USA"
650 2 $aPeptidyl-Dipeptidase A.$0https://id.nlm.nih.gov/mesh/D007703
650 2 $aEnzyme Inhibitors$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D004791Q000627
650 2 $aAntihypertensive Agents.$0https://id.nlm.nih.gov/mesh/D000959
650 2 $aPhosphinic Acids$xtherapeutic use.$0https://id.nlm.nih.gov/mesh/D010721Q000627
700 1 $aKaplan, Norman M.,$d1931-2020.$0http://id.loc.gov/authorities/names/n79135086
740 0 $aProfile of a new ACE inhibitor.
830 0 $aDrug investigation supplement ;$vv. 3, suppl. 4.
852 80 $boff,hsr$hSerial$iD